WHO Sounds Concern Over Severe Scarcity of Obesity Injections
Less than 10% of individuals who could benefit from weight-loss injections such as Wegovy can access them, states the global health agency as it publishes its inaugural advice on the therapies.
Considering in excess of 1,000,000,000 individuals worldwide now living with obesity, it is urging increased and just availability to GLP-1 medication.
Based on estimates, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"Our latest guidelines affirms that excess weight is a chronic disease that can be treated with thorough and ongoing treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are significant obstacles to universal access to the treatments that can help people shift considerable body mass, notes the body.
Weight-Loss Drug Shortage
Even under the current best projected case, the manufacturing of such drugs could only cover approximately 100 million people – under 10% of the global need, as stated by the health organization.
The recommendation encourages governments and firms to expand availability, via measures including voluntary licensing.
A patent on the active ingredient – the primary ingredient of the drug Wegovy – is set to lapse in several nations in 2026.
The Way Obesity Injections Operate
The injections mimick a natural hormone to slow digestion, curb appetite and boost satiety so individuals reduce food intake.
People usually begin shedding pounds in the initial weeks of starting on the regular doses.
Research points to users may put most of the weight back on within a year of stopping the medication, as their typical hunger come back.
To be overweight or obese raises your likelihood for experiencing health problems, including type 2 diabetes, heart disease, brain attack, and some malignancies.
Obesity affects people in every country and was associated with millions of deaths worldwide in 2024, as per the health agency.
